Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

re products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Janssen Research & Development, LLC nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) 

Media contacts:
Ernie Knewitz
Phone: (908) 927-2953
eknewitz@its.jnj.com

Christina Chan
Phone: (908) 927-5769
cchan20@its.jnj.com

Investor contacts:
Stan Panasewicz
Phone: (732) 524-2524

Louise Mehrotra
Phone: (732) 524-6491


'/>"/>
SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015   ndd Medical Technologies ... (PFT) that employs precise ultrasound technology, announced that its ... held by the San Antonio Pulmonary Fibrosis Support Group. ... or pulmonary fibrosis (PF), as well as those suspected ... footprint of a mere 12 square inches, EasyOne Pro ...
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Phase III data shows significant antitumor benefit in patients ... Early data show that at eight weeks of treatment, ... patients with advanced liver cancer - New data ... better cognitive function than those taking tamoxifen - ...
... May 27 Researchers have discovered a novel molecular path ... , a disease that mainly affects women and slowly ... finding, significant because it is a first step toward developing ... the June 11, 2009, issue of the New ...
Cached Medicine Technology:Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 2Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 3Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 4Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 5Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 6Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 7Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 8Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 9Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 10Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 11Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 12Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 13Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 14Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 15Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 16Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 17Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 18Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 2Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 3Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 4
(Date:3/6/2015)... As the Mayo Clinic's 2012 published ... & Associates Nationwide Legal Services, A.P.C., comments on these ... Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in ... “In light of a recently filed lawsuit, Ford & ... and explore the Mayo Clinic's Benicar case study findings ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host to ... include the following activities:, October 5: ... 6: Conference Day 1, ending with a Fashion Show and ... with Local Entertainment and Dinner , October 8: ... , October 9-10: Textiles in India Tour (optional; ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 The global digital PCR ... 2019, at CAGR of 7.8% from 2014 to 2019. , The ... at a CAGR of 7.8% from 2014 to 2019. Although the ... larger shares in the digital PCR (dPCR) and qPCR market the ... 10.7% in the forecast period. The growth of the digital PCR ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 ... company focused on the peripheral nerve repair market, reported ... ended December 31, 2014 compared to $2.98 million in ... of its growth strategies. , “Our strong fourth ... our peripheral nerve repair products which is driving increased ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... the past decade, Asia has been the preferred destination ... medical treatments. The increase is partially due to high ... and United Kingdom. Specialized treatments, surgeries and therapies are ... cost, yet with bigger perks when it comes to ...
... Amber Court ( http://www.AmberCourtAL.com ) reaffirms its ... Public Advocate Ronald K. Chen,s investigation of Wisconsin-based Assisted ... depleted their personal savings. , ... of Amber Court Assisted Living ...
... April 21 When Gundersen Lutheran Health System set out ... to 2 percent decrease that,s common at healthcare facilities. Instead, ... less than two years. That,s 9,600 metric tons of carbon ... equivalent of removing 1,631 cars from the road. The La ...
... receive Magnet re-designation.DALLAS, April 21 The American ... Baylor University Medical Center at Dallas (Baylor ... effective immediately. Fewer than six percent of hospitals ... and merely two percent of the nation,s hospitals ...
... (BRONX, NY) Recurrent and metastatic endometrial and ... have spread to other organs and typically have developed ... chemotherapy may not be able to endure more chemo. ... Yeshiva University have shown that a combination of two ...
... Blue Cross and Blue Shield of Minnesota and ... financial results for 2008. The organization reported an overall ... revenues of $8.8 billion, with $8.0 billion paid to ... deficit was the result of net realized capital losses ...
Cached Medicine News:Health News:Medical Tourism is Good Therapy for the Hotel Industry 2Health News:Medical Tourism is Good Therapy for the Hotel Industry 3Health News:Medical Tourism is Good Therapy for the Hotel Industry 4Health News:Medical Tourism is Good Therapy for the Hotel Industry 5Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2008 Financial Results 2
... The Finnpipette Digital offers improved ... The rounded handle, modified grippy finger ... enhance operator comfort and efficiency. Finnpipette ... with power-boosted gearing mechanism (pat. pend.) ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Medicine Products: